Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled insulin Clear all
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

NCT00355849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

NCT01982604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TI-Inhalation Powder A, TI-Inhalation Powder B
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

NCT00157339
View directory record Official record
Conditions
Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Human Insulin Inhalation Powder, injected insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
36
States / cities
Montgomery, Alabama • Burbank, California • Greenbrae, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 3, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

NCT00322257
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
inhaled human insulin, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

NCT00437112
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 3, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

NCT00523042
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
insulin aspart, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 2 Interventional

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Fresno, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

NCT01490762
View directory record Official record
Conditions
Healthy
Interventions
Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus

NCT01786707
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Autologous stem cells, Hyperbaric oxygen therapy, Insulin, Metformin
Biological · Other · Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
45 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

NCT03324776
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Model Clinical Research LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Not applicable Interventional Results available

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

NCT00509223
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Positive Airway Pressure therapy, Lifestyle counseling
Device · Behavioral
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 3, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

NCT00700622
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Technosphere Insulin, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

NCT00391209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Santa Ana, California • Washington D.C., District of Columbia • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

NCT00424333
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled human insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
30
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Sep 3, 2026, 10:50 PM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

NCT00356421
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

NCT00325364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Injectable insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Sacramento, California • Santa Ana, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 3, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

NCT00136916
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Dose Titration Study

NCT00246623
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education
Drug · Procedure · Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2008 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 4 Interventional Results available

Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

NCT00359801
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
132
States / cities
Bay Minette, Alabama • Fairhope, Alabama • Graysville, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Sep 3, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

NCT00479258
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Sep 3, 2026, 10:50 PM EDT
Not listed Phase 4 Interventional

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

NCT03313960
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Afrezza plus One Drop | Premium, One Drop | Premium
Drug · Other
Lead sponsor
Informed Data Systems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 3, 2026, 10:50 PM EDT
Completed Phase 4 Interventional Results available

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

NCT00418522
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Inhaled Insulin (Exubera)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 10:50 PM EDT
Withdrawn Not applicable Interventional

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

NCT01459133
View directory record Official record
Conditions
Diabetes
Interventions
Technosphere® Insulin Inhalation System
Drug
Lead sponsor
South Orange County Endocrinology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 3, 2026, 10:50 PM EDT